Background: Non-diabetic patients presenting with an acute stroke often have hyperglycaemia. In most populations it is unknown whether the hyperglycaemia is transient and due to the acute stress response or whether it represents undiagnosed abnormal glucose metabolism. Aim: To evaluate the prevalence and predictors of persistent hyperglycaemia in non-diabetic patients with an acute stroke. Design: Prospective observational study. Methods: Non-diabetic patients over 40 years old with an acute stroke were enrolled over a 2-year period. On admission patients were evaluated with an HbA 1c and a 75 g oral glucose tolerance test (OGTT). The OGTT was repeated 3 months later. A meta-analysis was performed to interpret our results in the context of published data. Results: One hundred and seven patients were analysed. On admission 26 (24%) patients had diabetes,
Introduction
There is a considerable global burden of diabetes. In the year 2000, an estimated 171 million people were affected by diabetes, whilst the excess global mortality attributable to diabetes was 2.9 million. This accounted for 5.2% of all deaths. 1 This excess mortality was primarily due to cardiovascular disease (CVD), and is likely to rise as an estimated 366 million people will have diabetes by the year 2030. 2 Diabetes also increases the risk of ischaemic stroke and is associated with a less favourable outcome than in people without diabetes. The importance of early initiation and maintenance of glycaemic control on all-cause mortality and myocardial infarction in people with diabetes has recently been demonstrated, adding to the well-recognized benefit of such control on microvascular complications. [3] [4] [5] Given these data, ideally diabetes should be diagnosed early, and treatment instituted prior to presentation with complications. Unfortunately this is often not the case. In a number of studies 50-60% of people who presented with an acute myocardial infarction were found to have undiagnosed diabetes. 6, 7 In addition, many people with newly diagnosed diabetes have pre-existing CVD as demonstrated in the ADDITIONCambridge screening and intervention study, in which 19% of screen positive people with diabetes had pre-existing CVD. 8 Patients without known diabetes commonly have hyperglycaemia at presentation of an acute stroke, making the diagnosis of diabetes difficult as the hyperglycaemia may occur as an acute stress response, [9] [10] [11] [12] may represent previously undiagnosed impaired glucose metabolism [13] [14] [15] [16] or may be a marker of infarct size. 8, 17, 18 Although there is no evidence that rendering these patients euglycaemic is beneficial from the point of view of mortality and morbidity from the stroke, there is evidence that preventing persistent hyperglycaemia in patients with diabetes reduces microvascular disease and CVD. 3, 4, 19 It is therefore clinically important to recognize these patients on admission so that they may benefit from long-term treatment with glucose lowering agents. However, there is a paucity of data on predictors of persistent hyperglycaemia in patients presenting with an acute stroke who are not known to have diabetes. We therefore investigated the prevalence and predictors of persistent hyperglycaemia in these patients. Furthermore, since there is currently no systematic review of the published literature on the prevalence of persistent hyperglycaemia in non-diabetic patients who have had an acute stroke, we analysed our results in the context of published data through a meta-analysis.
Methods Patients
Patients without known diabetes who were admitted to two participating hospitals with a diagnosis of acute stroke at specific times between July 2004 and 2006 were approached for participation in this study. Exclusion criteria included: being <40 years of age; having a haemaglobinopathy or chronic anaemia; being on chronic systemic glucocorticoid therapy, or having received such therapy in the last 1 month; inability to give consent. Acute stroke was defined according to the World Health Organisation (WHO) criteria i.e. rapidly developing clinical symptoms or signs of focal disturbance of cerebral function, lasting more than 24 h, with no apparent cause other than vascular origin. 20 The diagnosis of stroke was established by history and neurological examination. Confirmation by computed tomography was obtained in a minority of patients due to problems of access. The research protocol was approved by the University of Cape Town Research and Ethics committee.
Protocol
Each patient fulfilling the selection criteria and having signed informed consent was enrolled into the study within 2 days of admission. After a 10-h overnight fast a plasma glucose and HbA 1c were measured. Serum lipids were measured on Days 2 or 3 and a standard 75 g oral glucose tolerance test (OGTT) was performed on Days 3 or 4 of admission. During the acute admission the following sociodemographic and clinical data was collected: age, gender, ethnicity, previous history of hypertension and dyslipidaemia, family history of diabetes, smoking, systolic blood pressure (BP), diastolic BP, height, weight and waist circumference. At least 3 months after discharge the OGTT was repeated only in those patients diagnosed with hyperglycaemia during the acute admission. A fasting serum insulin level was measured on the pre-test fasting blood and the degree of insulin resistance was estimated by the homeostasis model assessment (HOMA) method. 21 Definitions: diabetes-fasting plasma glucose (FPG) !7 mmol/l or 2-h plasma glucose during the OGTT ! 11.1 mmol/l; pre-diabetes-2-h plasma glucose during the OGTT ! 7.8 mmol/l but <11.1 mmol/l [impaired glucose tolerance (IGT)] or FPG ! 5.6 mmol/l but <7.0 mmol/l [impaired fasting glucose (IFG)]; dysglycaemia-diabetes plus pre-diabetes; normal glucose tolerance (NGT)-FPG < 5.6 mmol/l or a 2-h plasma glucose during the OGTT <7.8 mmol/l. 22, 23 Assays Plasma glucose was measured using the glucose oxidase method on samples collected in fluoride tubes. HbA 1c analysis was done by the Diabetes Control and Complications Trial (DCCT) method, with an upper range of 6.0%. Insulin was measured using a radioimmunoassay (Roche Modular E170).
Statistical analysis
Normality assumption was tested using ShapiroWilks test. Variables failing this assumption were transformed when appropriate. These variables are presented as median [interquartile range (IQR)] and were analysed using the non-parametric MannWhitney U-test. Categorical variables are presented as frequency (percentage) and were compared using the 2 or Fischer's exact test. The relationships between 3-month glycaemic status and biochemical parameters as explanatory variables were assessed using multiple and or logistic regression techniques. A receiver operating characteristic (ROC) curve was plotted to determine the cut-points for predictors of dysglycaemia and their sensitivity, specificity, and predictive values. Statistical analyses were performed using SPSS (version 16.0.1) for Windows (SPSS Inc.) and STATA (version 10.0).
Systematic review and meta-analysis

Review inclusion and exclusion criteria
Prospective cohort studies investigating the prevalence of dysglycaemia assessed according to WHO and American Diabetes Association (ADA) criteria in non-diabetic individuals with acute stroke were eligible for inclusion. 22, 23 Studies with missing admission data or having follow-up data <3 months were excluded, as were those of chronic stroke or acute stroke due to prosthetic valves.
Study identification and eligibility. Two independent observers (J.A.D. and M.E.E.) identified studies from the MEDLINE database (from its earliest date until December 2008) using a predetermined search strategy incorporating the terms ("GLUCOSE METABOLISM
) limited to articles with abstracts of studies conducted in adult participants. This process was complemented by reviewing citations and searching in Google Scholar. Language of publication was restricted to English articles only. Titles and abstracts were screened, and full text articles obtained from potentially eligible reports. We immediately excluded editorials and review articles.
Data extraction. From each study, we (J.A.D. and M.E.E.) independently recorded year of publication, study design, origin and demographics of participants, diagnostic criteria, disease information, prevalence and standard error of the estimate. Where not provided, confidence intervals (CIs) were incorporated into the formula, SE = (upper limit À lower limit)/3.92.
Data synthesis. Prevalence data from individual studies were combined by random-effects meta-analysis according to the Mantel-Haenszel method. Heterogeneity was evaluated using the 2 -based Q statistic (significant for P < 0.1). We also used the I 2 statistic, considering values above 56% to be indicative of 'notable' heterogeneity (Higgins). STATA software version 9.2 (STATA Corporation, College Station, Texas) was used to perform calculations and the meta-analysis and to produce the forest plots using the metan routine.
Results
One hundred and twenty-one patients were enrolled. Fourteen patients were excluded (one patient tested HIV-positive, three patients died before completing the questionnaire or admission OGTT, nine patients did not have an OGTT during the acute admission and one patient withdrew from the study) leaving 107 eligible patients who were included in this report.
Acute admission
Baseline clinical and biochemical characteristics are summarized in Table 1 . Sixty-five patients (61%) were dysglycaemic [26 (24%) had diabetes and 39 (37%) had pre-diabetes] and 42 (39%) had NGT. The dysglycaemic patients were more likely to be female (P < 0.01), had previous hypertension (P = 0.02) and a family history of diabetes (P < 0.01). In addition, they had higher systolic (P < 0.001) and diastolic (P < 0.01) BPs, a higher total cholesterol (P < 0.01) and a higher low-density lipoprotein (LDL) cholesterol (P < 0.01) than the patients with NGT. Unexpectedly, the latter patients were more likely to have ever smoked than the dysglycaemic patients (P < 0.01). This may be because more women were dysglycaemic and there were less women that ever smoked than men (P < 0.0001).
Subsequent review !3 months after discharge
Of the 65 patients with dysglycaemia on admission, 44 were re-investigated at !3 months after discharge; 41 with an OGTT and 3 patients with a FPG and HbA 1c because they were on oral hypoglycaemic agents ( Table 2) . The remaining 21 patients were not re-assessed due to death after discharge [13 (20%) patients: eight patients with diabetes and five patients with pre-diabetes] and inadequate contact details [8 (12%) patients]. Eighteen (41%) of the 44 patients re-investigated remained dysglycaemic [6 (14%) had diabetes, 12 (27%) had pre-diabetes] and 26 (59%) had NGT ( Table 2 ). The three patients on oral hypoglycaemic agents were considered to have diabetes as supported by their elevated FPG and HbA 1c despite treatment (Patient A: FPG 6.6 mmol/l, HbA 1c 6.7%; patient B: FPG 6.8 mmol/l, HbA 1c 6.6%; patient C: FPG 6.8 mmol/l, HbA 1c 6.3%). Of the 26 patients classified with diabetes during the acute admission, 5 (19%) remained diabetic, 6 (23%) had pre-diabetes and 6 (23%) had NGT (Table 3) . In the 39 patients with pre-diabetes during the acute admission, 1 (3%) developed diabetes, 6 (15%) remained with pre-diabetes and 20 (51%) reverted to NGT (Table 3) . Patients with dysglycaemia had a higher median HbA 1c (5.95%, IQR 5.5-6.4 vs. 5.5%, IQR 5.2-6.1; P = 0.04) and median homeostasis model assessment of insulin resistance (HOMA-IR) (3.5, IQR 2.7-4.7 vs. 1.4, IQR 0.9-2.2; P 0.001) than those with NGT, but age, gender, past history of hypertension or dyslipidaemia, family history of diabetes, current/previous smoking, body mass index (BMI), waist circumference, BP, triglycerides and high-density lipoprotein (HDL) did not differ between those with NGT or dysglycaemia.
On admission, patients that subsequently died had a significantly higher FPG than those alive at follow-up (10.4 AE 3.9 mmol/l, 95% CI: 8.8; 12 vs. 8.6 AE 3.3 mmol/l, 95% CI: 7.9; 9.3, P = 0.043) but there was no significant difference in HbA 1c .
Logistic regression analysis revealed the 2-h post-load glucose value on admission to be the only significant predictor of persistent dysglycaemia 3 months after discharge. A 2-h post-load glucose value !10 mmol/l predicted dysglycaemia with 72.2% sensitivity, 65.4% specificity and gave a positive predictive value (PPV) and negative predictive value (NPV) of 59.1 and 77.3%, respectively ( Table 4 ). The area under the ROC curve was 0.76 (95% CI: 0.61-0.90). Categorical variables presented as n (%) with P-values by the 2 test. Continuous variables presented as median (IQR) with P-values by the Mann-Whitney U-test for non-parametric data. BP: blood pressure.
Systematic review and meta-analysis
The search strategy yielded 935 citations. Records were screened by title after which 48 articles were deemed to be potentially relevant. Abstracts were evaluated by two observers working independently and 43 studies were excluded; following full-text scrutiny, one publication was excluded, while for a further two, the full text was unavailable. Reasons for exclusion were known diabetics included (n = 3), no glycaemic data provided (n = 5), no admission OGTT and no follow-up data at !3 months (n = 35).
Characteristics of the included studies
One publication (Vancheri) satisfied our inclusion criteria (Table 5) . Together with our unpublished data, the eligible studies pertained to two distinct study populations comprising 213 participants with median ages of 71.0 and 61.0 years, respectively. The proportions of men were 61 and 53%, (15) 20 (51) 8 (21) 4 (10) Data are n (%). F/U: follow-up.
respectively. For the outcome of interest, a total of 125 subjects were included in the analysis. Both were observational studies conducted in Italy and South Africa, respectively and both classified impaired glucose metabolism according to WHO and ADA criteria. Meta-analysis of prevalence data of dysglycaemia in non-diabetic individuals 3 months after having had an acute stroke revealed a combined prevalence of 58% (95% CI: 25.4-90.5%) ( Table 5) . Statistically significant heterogeneity [heterogeneity 2 significant (P < 0.01), I 2 > 90%] was found across the studies.
Discussion
In this prospective study, the second to evaluate glucose homeostasis in patients without a prior diagnosis of diabetes and an acute stroke, using a FPG and OGTT on admission and again within 3-12 months after discharge, 61% of patients were found to be dysglycaemic (24% had diabetes and 36% pre-diabetes) on admission. However, by 3-12 months after discharge the majority (59%) had NGT leaving an overall prevalence of persistent dysglycaemia of 21% (7% with diabetes and 14% with pre-diabetes). The 2-h post-load blood glucose on admission was most predictive of dysglycaemia at 3 months.
Although the prevalence of dysglycaemia on admission was high in this study, it was lower than that reported in the only other study using a FPG and OGTT to evaluate glucose homeostasis on admission and again at least 3 months later. 16 In that study, the prevalence of dysglycaemia on admission was 84.3% (45.8% had diabetes and 38.5% IGT). The higher prevalence may be due to the older age of their patients (69.6 years, IQR 63.2-76.7 vs. 61 years, IQR 51.0-71.0). Interestingly, the majority Only patients that were dysglycaemic at admission were re-evaluated.
(74%) of their patients with dysglycaemia on admission remained dysglycaemic when re-tested 3 months after discharge (43% had diabetes and 31% IGT) leaving their overall prevalence of dysglycaemia at 65% (37.5% with diabetes and 27.1% with IGT), suggesting a pre-existent abnormality of glucose metabolism in the majority of their patients. On the other hand, the majority of dysglycaemic patients in our study reverted to euglycaemia, indicating that the hyperglycaemia on admission was likely to be due to the acute stress response. It has been debated whether the acute stress response plays a significant physiological role, nevertheless, it is well-documented that the diabetogenic hormones cortisol and catecholamines are elevated in some patients with an acute stroke. 11, 12, 24 Whilst even in a population-based survey in rural Tanzania 80% of subjects with IGT reverted to NGT within 5 days, partly attributable to the 'orienting reflex' in BP measurements in a population unfamiliar with blood testing. 25 Patients in developing countries present later in the course of their illness, which in the case of an acute stroke may result in a larger infarct area and higher blood glucose. The causal relationship between hyperglycaemia and larger infarcts remains unknown, but is speculated to be due to increased oxidative stress and inflammation found in the setting of hyperglycaemia. 26 Interestingly, the patients in this study that died had a higher fasting blood glucose level on admission than those that survived yet there was no difference in HbA 1c , suggesting pre-stroke euglycaemia and possibly larger and more severe cerebral infarcts. This is consistent with the study by Murros et al. that showed that pre-stroke hyperglycaemia (as suggested by an increased HbA 1c ) did not have any predictive value concerning stroke outcome but that post-stroke fasting hyperglycaemia correlated strongly with stroke severity and predicted stroke outcome. 27 They suggest that a high fasting blood glucose after a stroke reflects a stress response to a more severe ischemic brain lesion. Other studies in animals and humans have shown an association between hyperglycaemia and worse outcome after stroke in terms of both mortality and morbidity. 18, [28] [29] [30] Our study differs from most other studies that have assessed hyperglycaemia in the acute stroke setting in that it was designed a priori to examine the question of persistent hyperglycaemia. For that reason, only patients with hyperglycaemia on admission were re-examined. However, we were only able to re-investigate 68% of the dysglycaemic patients as 13 (20%) had died and 8 (12%) were lost to follow-up. The latter observation is probably due in large part to patients giving incorrect contact details so as to qualify for admission to their hospital of choice rather than the hospital closest to where they live. If one assumes that all those not re-examined became euglycaemic (best case scenario) or that they remained dysglycaemic (worst case scenario) then the lowest and highest prevalences of dysglycaemia are 28 and 60%, respectively. Even at 60%, the worst case scenario provides a much lower prevalence than described by Vancheri et al. 16 A dearth of factors examined on admission (including age, gender, smoking, previous history of hypertension, family history of diabetes, BP, lipids, BMI, waist circumference, HbA 1c , fasting insulin and HOMA) proved to be predictive of dysglycaemia at follow-up. Both the present study and that of Vancheri et al. found the 2-h post-load plasma glucose on admission to be most predictive of dysglycaemia at 3 months. This may be somewhat surprising as the poor reproducibility of the 2-h post-load glucose would be expected to cast doubt on its ability to be a predictive test. The use of a composite score including multiple diabetes risk factors such as waist girth or BMI, family history of diabetes, age and levels of physical activity may prove to be more useful and its utility should be explored in a larger cohort. This would permit early introduction of appropriate glucose lowering therapy and attainment of euglycaemia or close to euglycaemia immediately after the stroke, with the recognized benefits.
We attempted to analyse our results in the context of existing studies. However this systematic review highlights the lack of well-designed prospective studies utilizing both a FPG and 2-h post-load plasma glucose to identify dysglycaemic patients (as recommended by the WHO and ADA). We believe that most studies were likely to have missed patients with abnormal glucose metabolism on admission as they did not use a FPG and OGTT to diagnose dysglycaemia. In addition, most studies do not have follow-up glycaemic data and are therefore unable to assess the prevalence of persistent dysglycaemia. The studies by Kernan et al.
14 and Gray et al. 31 contain follow-up glycaemic data and are similar to those included in the meta-analysis, but are likely to have missed patients with abnormal glucose metabolism, as no OGTT was done on admission and only patients whose fasting blood glucose was within a specifically defined range were included. Lam et al. report a prevalence of 17 and 26% of diabetes and IGT, respectively in Chinese patients with a stroke and no prior diagnosis of diabetes. 28 As their report does not contain glycaemic data on admission, it is not possible to determine whether their reported prevalence is of persistent dysgycaemia or whether the dysglycaemia developed in these patients as a result of the stroke i.e. less physical activity, weight gain and the use of diabetogenic drugs such as b-blockers and/or thiazide diuretics. In our meta-analysis, the results showed significant heterogeneity. Procedurally, the studies were similar in almost every respect and thus, we suspect that this variation is due to the difference in the number of participants for which follow-up data were available. Nevertheless, a meta-analysis of these studies is still useful in providing an idea of the overall prevalence which indicates a combined prevalence of persistent dysglycaemia of 58%.
It is concerning that a significant number of stroke patients with no prior history of diabetes have their first clinical presentation of dysglycaemia as an acute stroke. It seems that opportunistic screening of individuals with risk factors for diabetes who attend a health service will allow for earlier diagnosis and initiation of therapy and a chance to avert or delay micro and macrovascular complications. Indeed, the ADDITION-Cambridge study has shown that people with screen-detected type 2 diabetes have an adverse cardiovascular risk profile and that a significant absolute reduction in this risk is achievable through multifactorial therapies. 8 Since a proportion of hyperglycaemic non-diabetic stroke patients will have transient hyperglycaemia or prediabetes, it is important that these patients undergo strict lifestyle modification and are re-assessed with an OGTT at least 3 months after discharge.
In conclusion, we report a high prevalence of transient dysglycaemia in patients with an acute stroke. It is concerning that at least 21% of patients in our study had undiagnosed dysglycaemia. In agreement with studies post-myocardial infarction and in the absence of significant predictive factors we suggest a follow-up OGTT at least 3 months after discharge in hyperglycaemic acute stroke patients with no prior history of diabetes.
